Based on our findings, we therefore, propose that these tumors should be regarded as “neuroendocrine carcinoma related”, either characterized by IDH2 mutations (neuroendocrine carcinoma-like, IDH2 mutant) or recurrent SMARCA4/ARID1A alterations (neuroendocrine carcinoma-like, SMARCA4/ARID1A enriched). The gene discussed is ARID1A; the disease is neuroendocrine carcinoma.